Develops bispecific antibody therapies for cancer treatment, focusing on immuno-oncology and targeted therapies.
Merus N.V., based in Utrecht, the Netherlands, is an innovative clinical-stage immuno-oncology company dedicated to pioneering bispecific antibody therapeutics. Established in 2003, Merus focuses on discovering and developing novel therapies that harness the power of bispecific antibodies to target cancer. One of its prominent candidates is Zenocutuzumab (MCLA-128), currently advancing through Phase 2 clinical trials for metastatic breast cancer, with additional Phase 1/2 trials underway targeting solid tumors harboring Neuregulin 1.
Merus' robust pipeline includes MCLA-158, currently in Phase 1 trials for the treatment of solid tumors, and MCLA-145, advancing through Phase 1 trials targeting various solid tumors. The company is also progressing MCLA-129 through Phase 1/2 trials for advanced non-small cell lung cancer and other solid tumors, and ONO-4685 through Phase 1 trials for relapsed/refractory T cell lymphoma. Collaborative efforts include partnerships with Betta Pharmaceuticals Co. Ltd for the development of MCLA-129 and Incyte Corporation for the advancement of MCLA-145, underscoring Merus' strategic approach to expanding its bispecific antibody portfolio.
With a steadfast commitment to innovation and clinical excelence, Merus N.V. continues to drive forward in its mission to transform cancer treatment paradigms. By leveraging cutting-edge research and strategic collaborations, Merus aims to deliver impactful therapies that address significant unmet medical needs and improve patient outcomes worldwide.